Open access
Open access
Powered by Google Translator Translator

Study: Half of Trials Supporting New Cancer Drug Approvals in Europe Were Judged to be at High Risk of Bias

20 Sep, 2019 | 07:46h | UTC

Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis – The BMJ (free)

Editorial: Flawed evidence underpins approval of new cancer drugs (free)

Commentaries: Gauging the validity of cancer drug trials: a call for collaboration – The BMJ Opinion (free) AND Questions raised over quality of trials supporting new cancer drugs approvals – OnMedica (free) AND Evidence underpinning approval of new cancer drugs raises questions – The BMJ (free)

“Around half of trials that supported new cancer drug approvals in Europe between 2014 and 2016 were judged to be at high risk of bias, which indicates that treatment effects might have been exaggerated, concludes a new study.” (from The BMJ news release)

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.